Synexus
Clinical trials specialist Synexus has opened an additional three dedicated research centres in Bulgaria, Poland and Romania, bringing the total to nine centres in Eastern Europe and 25 across Europe and Africa. These new centres provide the company’s clients in pharma and CROs with an expanding pool of patients.
Synexus, based in the UK, is a multi-national company focused on the recruitment and running of clinical trials at its own 25 dedicated research centres and 24 affiliated sites. The population of Central and Eastern European countries exceeds that of either the US or the five largest Western European markets combined, which is the reason it has continued to remain important to the clinical trials market.
The new Polish research centre is Synexus’ largest, occupying 1000 m2 at Beniowskiego Street, in Gdansk. Dr. Magdalena Przekwas-Jaruchowska, the centre’s director, oversaw the opening ceremony, which included representatives from the local authority, the British Embassy, the medical university and patients’ associations.
Romania’s new 820 m2 centre is based in the capital Bucharest, which has a population of two million. Romania has been part of Synexus’ development plans since early 2000, as the country’s total population is over 20 million and the number of new clinical trials granted approval during the last five years is at least 200.
The dedicated research centre in Bulgaria is situated in Sofia and covers 650 m2, with eight medical rooms, two administration rooms, monitoring and meeting rooms and other areas. This is an innovative project for Bulgaria, which aims to offer its patients access to new drugs in a number of fields including pulmonology, rheumatology, neurology, endochrinology, cardiology, gastroenterology and dermatology.
All Synexus’ 25 clinics across Europe and Africa focus on undertaking clinical trials in the therapy areas where the company can provide most value. Particular attention is devoted to the areas of cardiovascular, metabolic (diabetes and obesity), musculoskeletal, respiratory and central nervous system (dementia and pain) trials.
The new Dedicated Research Centres in Bulgaria, Poland and Romania provide Synexus with a further platform to build on existing success. Both patients and the pharmaceutical industry alike will benefit from the increased ability to develop clinical research capabilities across the region.